Original Articles

The relationship of Soluble Suppression of Tumorigenicity 2 (sST2) and Troponin T (TnT) levels in Acute Myocardial Infarction (AMI) patients at Sanglah General Hospital, Bali, Indonesia

Made Minarti Witarini Dewi, Ni Kadek Mulyantari, Anak Agung Wiradewi Lestari , I Putu Yuda Prabawa

Made Minarti Witarini Dewi
Clinical Pathology Specialist Program, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

Ni Kadek Mulyantari
Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

Anak Agung Wiradewi Lestari
Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia. Email: aa_wiradewi@yahoo.com

I Putu Yuda Prabawa
1Clinical Pathology Specialist Program, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia ; 2Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia
Online First: July 11, 2021 | Cite this Article
Dewi, M., Mulyantari, N., Lestari, A., Prabawa, I. 2021. The relationship of Soluble Suppression of Tumorigenicity 2 (sST2) and Troponin T (TnT) levels in Acute Myocardial Infarction (AMI) patients at Sanglah General Hospital, Bali, Indonesia. Indonesia Journal of Biomedical Science 15(2): 87-91. DOI:10.15562/ijbs.v15i2.314

Background: Acute Myocardial Infarction (AMI) as cardiovascular disease is a significant cause of death worldwide and requires examining cardiac biomarkers such as Troponin T (TnT) for diagnosis. However, increased troponin levels are often found in non-AMI patients. Soluble Suppression of Tumorigenicity 2 (sST2) as a novel biomarker has known will increase after the occurrence of AMI. This study aims to evaluate the relationship of sST2 and TnT levels in AMI patients at Sanglah General Hospital, Bali, Indonesia

Methods: The study was conducted among 61 participants during August-December 2020 by consecutive sampling. The samples were examined for TnT levels using a Roche Cobass h232 and sST2 with the Human sST2 Elabscience© Enzyme-linked Immunosorbent Assay (ELISA) Kit. Normality and correlation tests were performed between the two parameters. Data were analyzed using SPSS version 17 for Windows.

Results: The average age of participants was 59.5±10.0 years old. Most of the participants were male and had hypertension history in STEMI (71.0% and 67.7%) and NSTEMI (70.0% and 79.0%) groups. There is no significant difference in BMI between STEMI (23.5±3.1 kg/m2) and NSTEMI (24.6±3.8 kg/m2) (p=0.319). However, there was a significant moderate positive correlation between TnT and sST2 levels (r=0.394, p=0.002).

Conclusion: There was an increase in troponin T and sST2 levels in AMI patients at Sanglah Hospital. There is a significant positive correlation between sST2 levels and troponin T levels in AMI patients at Sanglah Hospital.  


Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013;18(12):15314-28.

Dattagupta A, Immaneni S. ST2: Current status. Indian Heart J. 2018;70 Suppl 1(Suppl 1):S96-S101.

Meijers WC, van der Velde AR, Pascual-Figal DA, de Boer RA. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015;763(Pt A):115-121.

Stelzle D, Shah ASV, Anand A, Strachan FE, Chapman AR, Denvir MA, et al. High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. Eur Heart J Qual Care Clin Outcomes. 2018;4(1):36-42.

Prabawa IPY, Lestari AAW, Muliarta IM, Mardhika PE, Pertiwi GAR, Bhargah A, et al. The Stromal Cell-derived Factor-1/CXCL12 3’A-gene Polymorphism is Related to the Increased Risk of Coronary Artery Disease: A Systematic Review and Meta-analysis. Open Access Macedonian Journal of Medical Sciences. 2020;8(F):197-202.

Petyunina, OV, Kopytsya MP, Berezin AE. Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction. Biomedical Research and Therapy. 2018;5(12):2863-2875

Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113(14):1708-1718.

Michel JB, Schussler JM. The trouble with troponin. Proc (Bayl Univ Med Cent). 2018;31(2):238-239.

Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014;9(4):e95055.

Marino R, Magrini L, Orsini F, Russo V, Cardelli P, Salerno G, et al. Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain. Ann Lab Med. 2017;37(2):137-146.

Roche Diagnostic. Roche Cardiac POC Troponin T. Cobas System. 2019:230-232

Elabscience. Human sST2 (Soluble ST2) ELISA Kit. 2020.

Díez J, Bayes-Genis A. Compelling Benefit of Soluble Suppression of Tumorigenicity-2 in Post-Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. J Am Heart Assoc. 2017;6(10):e007665.

Kokkoz Ç, Bilge A, Irik M, Dayangaç HI, Hayran M, Akarca FK, et al. Prognostic value of plasma ST2 in patients with non-ST segment elevation acute coronary syndrome. Turk J Emerg Med. 2018;18(2):62-66.

Dudas K, Björck L, Jernberg T, Lappas G, Wallentin L, Rosengren A. Differences between acute myocardial infarction and unstable angina: a longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). BMJ Open. 2013;3(1):e002155.

Nah EH, Cho S, Kim S, Cho HI. Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups. J Clin Lab Anal. 2020;34(11):e23461.

Zhu J, Su X, Li G, Chen J, Tang B, Yang Y. The incidence of acute myocardial infarction in relation to overweight and obesity: a meta-analysis. Arch Med Sci. 2014;10(5):855-862.

St?pie? M, St?pie? A, Wlaze? RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis. 2014;13:29.

Arab TMA, Amin HM, Zahwy SSE. Impact of Body Mass Index on Presentation and Outcome of Acute Segment Elevation Myocardial Infarction. Journal of Cardiology and Current Research. 2017;9(2):00314

Borgeraas H, Hertel JK, Svingen GF, Seifert R, Pedersen EK, Schartum-Hansen H, et al. Association of body mass index with risk of acute myocardial infarction and mortality in Norwegian male and female patients with suspected stable angina pectoris: a prospective cohort study. BMC Cardiovasc Disord. 2014;14:68.

Ates I, Ozkayar N, Ates H, Karakulak UN, Kursun O, Topcuoglu C, Inan B, Yilmaz N. Elevated circulating sST2 associated with subclinical atherosclerosis in newly diagnosed primary hypertension. Hypertens Res. 2016;39(7):513-8.

Yin X, Cao H, Wei Y, Li HH. Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model. Hypertens Res. 2019;42(11):1664-1671.

Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One. 2012;7(10):e47830.

Severino P, D'Amato A, Netti L, Pucci M, Infusino F, Maestrini V, et al Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow. J Diabetes Res. 2019;2019:9489826.

Priyanto H, Nugraha J, Edijanto SP. Diagnostic Value of ST2 in Patients with Acute Myocardial Infarction. Folia Medica Indonesia. 2015;51(2):106-109.

Skeik N, Patel DC. A review of troponins in ischemic heart disease and other conditions. Int J Angiol. 2007;16(2):53-58.

Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2(1):65-72.

Jenkins WS, Roger VL, Jaffe AS, Weston SA, AbouEzzeddine OF, Jiang R, et al. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am J Med. 2017;130(9):1112.e9-1112.e15.

Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016;106(2):145-152.

Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243-50.

Kercheva M, Ryabova T, Gusakova A, Suslova TE, Ryabov V, Karpov RS. Serum Soluble ST2 and Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction. Clin Med Insights Cardiol. 2019;13:1179546819842804.

Mueller T, Jaffe AS. Soluble ST2--analytical considerations. Am J Cardiol. 2015;115(7 Suppl):8B-21B.

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961-2966.

Kercheva M, Gusakova AM, Ryabova TR, Suslova TE, Kzhyshkowska J, Ryabov VV. Serum Levels of Bone Morphogenetic Proteins 2 and 4 in Patients with Acute Myocardial Infarction. Cells. 2020;9(10):2179.

Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):2186-90.

Tymi?ska A, Kap?on-Cie?licka A, Oziera?ski K, Budnik M, Wancerz A, Sypie? P, et al. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. Dis Markers. 2019;2019:9529053.

Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-2064.

Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135(22):e1054-e1091.

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0